CannTrust brings more than 40 years of pharmacy and healthcare
CannTrust is a federally regulated licensed producer, who brings more than 40 years of pharmacy and healthcare experience to the Medical Cannabis industry. We apply this expertise to produce 100% pesticide free standardized Medical Cannabis for patients in need.
At CannTrust™ we are committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive pharma partner Apotex are diligently innovating and developing products. CannTrust has been granted a Section 9 License by Health Canada under the Narcotic Control Regulations. This allows us to expand our product development and research to include pharmaceuticals in an effort to make it easier for patients to use Medical Cannabis today and in the future.
Our onsite laboratory with advanced technology and equipment for testing and research on the medical use of cannabis provides CannTrust with the ability to develop and rigorously test our products at any point.
We continue to evolve our patient and medical practitioner education program about Medical Cannabis, and have an industry leading compassionate use program to support patients with financial needs.
We continue to expand to ensure we have a continuous supply of quality standardized products and superior customer service. Our original 50,000-square foot state-of-the-art hydroponic facility is home to cultivating, processing extracts and our distribution center.
Our second facility is a 430,000-square foot greenhouse in the heart of the Niagara region. The facility is the first of its kind in the Canadian Cannabis industry to be designed and engineered using advanced perpetual growing technology. This facility is one of the largest in North America, with Phase 1 completed and Phase 2 to come on-stream in mid 2018.
CANNTRUST POSITIONED FOR RAPID GROWTH AS CANADA’S…
CannTrust Holdings Inc. (“CannTrust” or the “Company”) (TSX: TRST), one of Canada’s leading licensed producers of Cannabis, is applauding the granting of Royal Assent to Bill C-45, the Cannabis Act. With Royal Assent received, the legislation legalizing cannabis for adult consumer use has now passed its final official step, and retail sales are to commence on October 17, 2018, as announced by Canada’s federal government.
CannTrust is excited and well-positioned to enter this new marketplace and has the production capacity and infrastructure together with standardized products with precise label claims indicating the exact dosage, to immediately begin fulfilling adult consumer use market orders on a national level.
“While the federal government has recently announced the commencement date for adult consumer use, CannTrust has been working towards this date for a very long time. We are well positioned for this rapid growth with our new product offerings, infrastructure, research and development and staffing. At the same time we continue to lead the medical industry through our customer support, innovative portfolio and most of all, our trusted standardized products. Initial adult consumer use order discussions with the Provinces have exceeded our preliminary estimates reflecting the market’s confidence in our abilities and the understanding of our consistent quality. This truly is an exciting and momentous time for both our Company and our nation”, says Brad Rogers, President of CannTrust.
CannTrust will apply its proven disciplined and scientific expertise approach, an approach that differentiates the Company from the other LPs in the medical arena, to the adult consumer use market. CannTrust is respected by both medical customers and practitioners for its standardized products and the Company will bring this same meticulous process to its adult consumer use offerings, providing a welcomed consistency to this new marketplace.
CannTrust is initially launching three recreational brands of Cannabis in Canada – liiv, SYNR.G and Xscape. This trio of brands will address the needs of three distinct target audiences: the knowledgeable enthusiast, the social consumer and the experience seeker. Each of the brands will include a set of carefully curated strains and the products will be available in a variety of formats including dried flower, pre-rolls, oils and capsules.